Merrimack Pharmaceuticals Stock Earnings Per Share
Merrimack Pharmaceuticals fundamentals help investors to digest information that contributes to Merrimack Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Merrimack Stock. The fundamental analysis module provides a way to measure Merrimack Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Merrimack Pharmaceuticals stock.
Merrimack |
Merrimack Pharmaceuticals Company Earnings Per Share Analysis
Merrimack Pharmaceuticals' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Merrimack Pharmaceuticals Earnings Per Share | (0.09) X |
Most of Merrimack Pharmaceuticals' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Merrimack Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Merrimack Pharmaceuticals has an Earnings Per Share of -0.09 times. This is 101.08% lower than that of the Biotechnology sector and 98.12% lower than that of the Health Care industry. The earnings per share for all United States stocks is 102.88% higher than that of the company.
Merrimack Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Merrimack Pharmaceuticals' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Merrimack Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Merrimack Pharmaceuticals by comparing valuation metrics of similar companies.Merrimack Pharmaceuticals is currently under evaluation in earnings per share category among its peers.
Merrimack Fundamentals
Return On Equity | -0.0112 | |||
Return On Asset | -0.0107 | |||
Current Valuation | (20.36 M) | |||
Shares Outstanding | 14.79 M | |||
Shares Owned By Insiders | 1.19 % | |||
Shares Owned By Institutions | 62.97 % | |||
Number Of Shares Shorted | 842.49 K | |||
Price To Earning | 65.70 X | |||
Price To Book | 11.38 X | |||
Gross Profit | (9.1 M) | |||
EBITDA | (2.18 M) | |||
Net Income | (1.18 M) | |||
Cash And Equivalents | 13.36 M | |||
Cash Per Share | 1.00 X | |||
Debt To Equity | 33.90 % | |||
Current Ratio | 31.85 X | |||
Book Value Per Share | 15.25 X | |||
Cash Flow From Operations | (1.52 M) | |||
Short Ratio | 8.65 X | |||
Earnings Per Share | (0.09) X | |||
Price To Earnings To Growth | 0.07 X | |||
Target Price | 4.0 | |||
Beta | 1.42 | |||
Market Capitalization | 223.75 M | |||
Total Asset | 19.19 M | |||
Retained Earnings | (548.82 M) | |||
Working Capital | 18.74 M | |||
Current Asset | 89.62 M | |||
Current Liabilities | 88.28 M | |||
Net Asset | 19.19 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Merrimack Stock
If you are still planning to invest in Merrimack Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Merrimack Pharmaceuticals' history and understand the potential risks before investing.
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |